20/20 Biolabs, Inc. AIDX
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -- | -0.93% | -- | 34.78% | 7.45% |
| Total Depreciation and Amortization | -- | -36.60% | -- | -31.07% | -22.37% |
| Total Amortization of Deferred Charges | -- | 14,120.00% | -- | 173.02% | -100.00% |
| Total Other Non-Cash Items | -- | -32.63% | -- | -38.69% | 79.12% |
| Change in Net Operating Assets | -- | 3.43% | -- | -18.02% | 57.39% |
| Cash from Operations | -- | -15.90% | -- | 36.96% | 39.25% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | 1,569.29% | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | 1,052.60% | -- | 64.92% | 268.73% |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | 969.23% | -- | 468.13% | 874.14% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -- | 244.36% | -- | 63.76% | 51.73% |